Trial Profile
A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Ascending Dose Study of INS115644 Ophthalmic Solution in Subjects With Bilateral Ocular Hypertension or Early Primary Open Angle Glaucoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Latrunculin B (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 22 May 2014 New trial record